Clinical Trials Directory

Trials / Completed

CompletedNCT04170088

Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma

Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma; a Split Face Study in Tertiary Care Hospital of Karachi

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Jinnah Postgraduate Medical Centre · Other Government
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

It is a randomized controlled trial in which investigators determine the efficacy of tranexamic acid (TA) by mesotherapy in comparison to normal saline on participants having Melasma.

Detailed description

In this prospective single blind split face controlled trial.Total 30 patients referred to Dermatology Ward were selected. At first, patients were examined under wood lamp for determination of melasma type (epidermal, dermal). Then, patients underwent Tranexamic acid microinjections with a concentration of TA 4 mg/ml with 0.9 % normal saline on their left half of the face and only 0.9%normal saline on their right half of the face, with mesotherapy technique. This procedure was done total of six times with 2-week intervals. Participants were assessed by Hemi Modified Melasma Area and Severity Scoring (mMASI) at start and end of the study for each half of face. Statistical Package for Social Sciences (SPSS) , version 23 was used for analysis. P value \< 0.01 was taken significant.

Conditions

Interventions

TypeNameDescription
DRUGTranexamic AcidTranexamic acid intradermal injections were used for treatment of melasma
DRUG0.9% Normal SalineNormal saline used for comparision of efficacy of tranexamic acid

Timeline

Start date
2018-09-01
Primary completion
2019-05-01
Completion
2019-06-30
First posted
2019-11-20
Last updated
2019-12-17

Locations

1 site across 1 country: Pakistan

Regulatory

Source: ClinicalTrials.gov record NCT04170088. Inclusion in this directory is not an endorsement.